Translations may contain older or less detailed information than the original German page!
Medicaments
Page overview:
Medication
The medication of histamine-related diseases like mast cell activity syndrome (MCAS), mastocytosis or histamine intolerance is described in detail in our SIGHI Medication Manual:
The SIGHI Medication Manual: pharmaceutical treatment of MCAD / Histaminosis
The SIGHI Medication Manual describes in detail and well-structured on more than 120 pages the different possibilities of medical treatment for systemic mast cell activation diseases, histamine intolerance or histaminosis and shows the advantages of numerous active substances as well as their disadvantages. In addition to pharmaceuticals, medical devices, foods for special medical purposes and dietary supplements are also explained. The Medication Manual explains the therapy concept and provides numerous suggestions for basic therapy and symptomatic additional treatment of the chronic phase as well as for the treatment of acute phases. It also presents treatment in special situations such as anaphylaxis / anaphylactic shock, infectious diseases, vaccinations, pollen allergies, pregnancy and breastfeeding, as well as premedication and other precautions regarding anesthesia, surgery and dental treatment. There is also a list of incompatible active substances and instructions on how to assess the tolerance of pharmaceutical products. This is complemented by many other tips and tricks.
SIGHI_Medication_Manual_PREVIEW.pdf (1 MB, version 2019-01-03) | |
SIGHI_Medication_Manual.pdf (3 MB, version 2019-01-03) |
Internal document for members only. No retail sale.
Here we can only briefly explain the most important classes of active ingredients:
Antihistamines
Antihistamines (histamine receptor antagonists) can be used to block the histamine receptors on the surface of cells. H1-receptors are blocked with H1-antihistamines to prevent most symptoms. Additionally, H2-receptors are blocked with an H2-antihistamine in case of excess gastric acid or other gastric / intestinal symptoms.
Diamine oxidase (DAO)
Diamine oxidase capsules can be taken before meals to decompose intestinal histamine before uptake. It has an effect only against histamine in foods, but not against histamine liberators and not against endogenous histamine released by mast cells.
Mast cell stabilisators
Some active substances are able to stabilise mast cells. Some act only locally, some are systemic.
Food supplements
Some food supplements like ascorbic acid, zinc or magnesium may have a slight positive effect. Ascorbic acid lowers the histamine level, but is also a slight DAO-inhibitor. It seems that ascorbic acid has a positive effect in mast cell diseases but may have negative effects in those concerned with histamine intolerance.
Incompatible medicaments
Histamine liberators
Many agents in medicaments (active substances as well as additives) have the negative effect that they cause mast cell degranulation which leads to release of histamine and other mast cell mediators. They have to be avoided where ever possible according to the agreement with your physician.
DAO-Inhibitors
Many agents in medicaments have the negative effect that they are diamine oxidase inhibitors or inhibitors of other histamine degrading enzymes. They have to be avoided where ever possible according to the agreement with your physician.
List of incompatible active substances in medicaments
This list needs to be completed. Please let us know your experiences with other substances.
Active substance | Examples of products ® | Categories | Histamine effects | References |
---|---|---|---|---|
Acemetacin | Antirheumatic | DAO inhibitor | [Sattler 1985, Fritzsche 2009] | |
Acetylcysteine | Fluimucil, Helvetussin, Muco-Mepha, NeoCitran, Solmucol | Mucolytic, antidote | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
Acetylsalicylic acid, ASS | Aspirin | Analgesic | Histamine liberator | [Jarisch 2004, Maintz et al. 2006] |
Acriflavin | Antiseptic | DAO inhibitor | [Fritzsche 2009] | |
Alcuronium | Muscle relaxant | DAO inhibitor | [Sattler 1985, Maintz et al. 2006, Forth 2008] | |
Alprenolol | Beta blocker | DAO inhibitor | [Maintz et al. 2006] | |
Ambroxol | Ambrovene, Ambroxol, Broxol, Mucosolvan, Mucospas | Expectorant | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
Amiloride | Diuretic | ? | [Maintz et al. 2006] | |
Aminocycline | DAO inhibitor | [Sattler 1985] | ||
Aminophyllin | Euphyllin, Mundiphyllin, Myocardon | Antiasthmatic | DAO inhibitor | [Sattler 1985, Jarisch 2004, Maintz et al. 2006] |
Amiphenazole | DAO inhibitor | [Sattler 1985] | ||
Amitriptyline | Saroten, Tryptizol, Limbritol | Tricyclic antidepressant | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
Amodiaquins | Antimalarials | HNMT-Blocker | [Horton et al. 2005, Aschenbach 2002] | |
Amphetamine | Histamine liberator | [Uni Bochum] | ||
Amphotericin B | Antibiotic | Histamine liberator | [Livingstone 2013, Büttiker] | |
Atracurium | Muscle relaxant | Histamine liberator | [Sido et al. 2014, Dewachter et al. 2014] | |
Atropine | Histamine liberator | [Büttiker] | ||
Barbiturates | Hypnotics, sedatives, anaesthetics | Histamine liberator | [Steneberg 2007] | |
Bile acids, bile salts | Histamine liberator | [Büttiker] | ||
Bupropion | NDRI | Histamine liberator | [Afrin et al. 2015] | |
Carbamazepine | Anticonvulsant | Histamine liberator | [Afrin et al. 2015] | |
Carbocromene | DAO inhibitor | [Sattler 1985] | ||
Cefotiam | Antibiotic | DAO inhibitor | [Maintz et al. 2006] | |
Cefuroxime | Antibiotic | Histamine liberator | [Sido et al. 2014, Maintz et al. 2006] | |
Chloroquine | Chlorochin, Nivaquine, Resochin | Antimalarials, antirheumatic | DAO inhibitor, HNMT-Blocker | [Sattler 1985, Jarisch 2004, Donatelli et al. 1994, Maintz et al. 2006] |
Chlortetracyclins | Antibiotic | Histamine liberator | [Büttiker] | |
Cimetidine | H2 antihistamine | DAO inhibitor | [Prof. Ralf Bauer Uni Bonn; found in: Jarisch 2004 S.12, Maintz et al. 2006, Fritzsche 2009] | |
Ciprofloxacin | Antibiotic | Histamine liberator | [Livingstone 2013, SIGHI: 1 Fallbericht] | |
Clavulanic acid | Augmentin | Antibiotic | DAO inhibitor | [Sattler 1985, Jarisch 2004, Maintz et al. 2006] |
Codeine | Opiate, analgesic, cough medicine | Histamine liberator | [Afrin et al. 2015, , Steneberg 2007] | |
Colistin mesilate | DAO inhibitor | [Sattler 1985] | ||
Curare | Arrow poison alkaloids, anaesthetic | [Büttiker] | ||
Cyclophosphamide | Cytostatic | ? | [Maintz et al. 2006] | |
D-Cycloserine | Seromycin | Antibiotic | DAO inhibitor (Vitamin B6-Antagonist) | [Sattler 1985, Steneberg 2007] |
Decamethonium | Histamine liberator | [Büttiker] | ||
Dextranes | Sephadex | Blood plasma substitute, antithrombotic | Histamine liberator | [Giertz und Hahn 1966, Büttiker] |
Diazepam | Valium | Tranquilizer | DAO inhibitor | [Fritzsche 2009] |
Diclofenac | Voltaren | Antirheumatic | Histamine liberator | [Jarisch 2004] |
Dihydralazine | Nepresol | Antihypertensive, vasodilator | DAO inhibitor | [Wantke et al. 1989, Sattler 1985, Maintz et al. 2006, Fritzsche 2009] |
Diphenhydramine | Nardyl, Benocten | Sedative, antihistamine | HNMT-Blocker | [Horton et al. 2005, Farag et al. 2008] |
Dipyrone: see Metamizol | ||||
Dobutamine | Antihypotonic | ? | [Maintz et al. 2006] | |
Fenpiverinium | DAO inhibitor | [Sattler 1985] | ||
Flurbiprofen | Histamine liberator | [Jarisch 2004] | ||
Framycetin | Antibiotic | DAO inhibitor | [Sattler 1985, Fritzsche 2009] | |
Furosemide | Lasix | Diuretic | DAO inhibitor | [Fritzsche 2009] |
Gadolinium chelates | X-ray contrast media | Histamine liberator | [Sido et al. 2014] | |
Gallamines | Histamine liberator | [Büttiker] | ||
Gelatine | Plasma substitute | Histamine liberator | [Sido et al. 2014] | |
Glyceroltrinitrate, glyceryltrinitrate, nitroglycerin, Propantrioltrinitrat | Vasodilator | Histamine liberator | [Pedersen et al. 2015] | |
Haloperidol | Haldol | Neuroleptic | DAO inhibitor | [Fritzsche 2009] |
Heroin | Histamine liberator | [Nesterenko 2010] | ||
Hydralazine | Histamine liberator | [Uni Bochum] | ||
Hydroxyethyl starch | Plasma substitute | Histamine liberator | [Sido et al. 2014] | |
Indomethacin | Histamine liberator | [Jarisch 2004] | ||
Isoniazide | Rimifon, Rifater | Tuberculostatic | DAO inhibitor (Vitamin B6-Antagonist) | [Jarisch 2004, Maintz et al. 2006] |
Ketoprofen | Histamine liberator | [Jarisch 2004] | ||
Latex gloves | Histamine liberator | [Sido et al. 2014] | ||
Levofloxacin | Antibiotic | Histamine liberator | [Sido et al. 2014] | |
Meclofenamic acid | Histamine liberator | [Jarisch 2004] | ||
Mefenamic acid | [Jarisch 2004] | |||
Meperidine: see pethidine | Opioid | |||
Metamizole, dipyrones | Novalgin, Minalgin | Analgesic, antipyretic | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
Methohexital | Injection narcotic | Histamine liberator | [Sido et al. 2014] | |
Metoclopramide | Migpriv, Paspertin, Primperan | Antiemetic, gastroenterologic, dopamine antagonist | DAO inhibitor | [Sattler 1985, Jarisch 2004, Maintz et al. 2006] |
Metoprine | HNMT-Blocker | [Horton et al. 2005, Jochem] | ||
Mivacurium | Muscle relaxant | Histamine liberator | [Sido et al. 2014, Dewachter et al. 2014] | |
Morphine | Analgesic, opioid | Histamine liberator | [Afrin et al. 2015, Maintz et al. 2006, Steneberg 2007, Forth 2008] | |
Naproxen | Histamine liberator | [Jarisch 2004] | ||
Nefopam | Analgesic | Histamine liberator | [Dewachter et al. 2014] | |
Neomycin | Antibiotic | DAO inhibitor | [Mathelier-Fusade 2006] | |
Nitroglycerin, glycerol trinitrate, glyceryl trinitrate, propane triol trinitrate | Vasodilator | Histamine liberator | [Pedersen et al. 2015] | |
Nonsteroidal anti-inflammatory drugs (NSAID) | Analgesic | Histamine liberator | [Sido et al. 2014] | |
Noscapine | Analgesic | Histamine liberator | [Büttiker] | |
Novamine sulfone | (=Metamizol) Novalgin, Minalgin | Analgesic, antipyretic | DAO inhibitor | [Jarisch 2004] |
NSAP, NSAR, NSAID | Verträglichkeit individuell! | NSAR, NSAID | (Histamine liberator) | [Afrin et al. 2015] |
Opiates, Opioids | (Heroin, Morphium) | Aalgesic | Histamine liberator | [Sido et al. 2014, Wirz and Molderings 2017] |
Orciprenaline | DAO inhibitor | [Sattler 1985] | ||
Pancuronium | Muscle relaxant | DAO inhibitor | [Sattler 1985, Maintz et al. 2006, Fritzsche 2009] | |
Papaverine | Histamine liberator | [Büttiker] | ||
Pentamidine | Antibiotic | DAO inhibitor | [Sattler 1985, Maintz et al. 2006] | |
Pethidine, Meperidine | Analgesic, opioid | Histamine liberator | [Sido et al. 2014, Wirz and Molderings 2017, Afrin et al. 2015, Maintz et al. 2006, Forth 2008] | |
Phenobarbital | Injection narcotic | Histamine liberator | [Sido et al. 2014] | |
Pilocarpine | Histamine liberator | [Büttiker] | ||
Pirenzepine | DAO inhibitor | [Sattler 1985] | ||
Polymyxin B | Antibiotic | Histamine liberator | [Büttiker] | |
Polyvinylpyrrolidone (E1201) | Povidone, PVP, Periston | Blood plasma substitute, antithrombotic, excipient in tablets and capsules | Histamine liberator | [Giertz und Hahn 1966, Novartis 2008] |
Prilocaine | Local anaesthetic | DAO inhibitor | [Maintz et al. 2006, Nesterenko 2010] | |
Procaine | Local anaesthetic | Histamine liberator | [Sido et al. 2014] | |
Promethazine | Atosil, Closin, Proneurin, Prothazin | Sedative, antihistamine, antipsychotic | DAO inhibitor | [Irion 2009] |
Propafenone | Rytmonorm | Antiarrhythmic | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
Propanidide | Anaesthetic | DAO inhibitor | [Nesterenko 2010] | |
Protamine | Heparin antagonization | Histamine liberator | [Sido et al. 2014; Horrow 1985] | |
Pyrazolones | Analgesic | Histamine liberator | [Büttiker] | |
Quinidine | Cardiac | DAO inhibitor | [Fritzsche 2009] | |
Quinine | Histamine liberator | [Büttiker] | ||
Reserpine | Histamine liberator | [Büttiker] | ||
Rifampicin | Antibiotic | Histamine liberator | [Livingstone 2013] | |
Rifaximin | Antibiotic | Histamine liberator | [1 Einzelfallbericht SIGHI] | |
Scopolamine | Histamine liberator | [Büttiker] | ||
SSRIs, selective serotonin reuptake inhibitors | Antidepressant | Unverträglich | [Afrin et al. 2015] | |
Stilbamidine | Histamine liberator | [Büttiker] | ||
Suxamethonium | Muscle relaxant | Histamine liberator | [Forth 2008Sido et al. 2014] | |
Tacrin | Acetylcholinesterase inhibitor, Alzheimer's drug | HNMT-Blocker | [Cumming and Vincent 1992, Taraschenko et al. 2005] | |
Teicoplanin | Antibiotic | Histamine liberator | [Livingstone 2013] | |
Tetracaine | Local anaesthetic | Histamine liberator | [Sido et al. 2014] | |
Tetroxoprim | DAO inhibitor | [Sattler 1985] | ||
Thiamine (vitamin B1) | (In parenteral administration. Compatible with food.) | Histaminliberator, DAO inhibitor | [Büttiker, Sattler 1985] | |
Thiopental | Sedative | Histaminliberator / DAO inhibitor ? | [Sido et al. 2014, Maintz et al. 2006] | |
Tolazoline | Histamine liberator | [Uni Bochum] | ||
Topiramate | Migraine, anti-epileptic | Histamine liberator | [Afrin et al. 2015] | |
tricyclic antidepressants | Unverträglich | [Afrin et al. 2015] | ||
Tubocurarins, D-Tubocurarin | Muscle relaxant | Histamine liberator | [Sattler 1985, Maintz et al. 2006, Forth 2008, Steneberg 2007] | |
Tyramine | Histamine liberator | [Uni Bochum] | ||
Vancomycine | Antibiotic | Histamine liberator | [Sido et al. 2014, Livingstone 2013] | |
Verapamil | Flamon, Isoptin, Tarka | Coronary vasodilatant, antihypertensive, antiarrhythmic, calcium antagonist | DAO inhibitor | [Jarisch 2004, Maintz et al. 2006] |
X-ray contrast media | All of them! | X-ray contrast media | Histamine liberator | [Jarisch 2004] |
ß-Adrenoceptor blockers | Histamine liberator | [Sido et al. 2014] |
Compatible alternatives
For compatible alternatives please have a look at the SIGHI Medication Manual.
Guided tour: go to
therapy > way of life
References and bibliography
The "back"-button of your browser takes you back to the previous position.
A | Back to the previous position |
---|---|
Afrin et al. 2015 | Afrin LB, Pöhlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ.: "Mast Cell Activation Disease: An Underappreciated Cause of Neurologic and Psychiatric Symptoms and Diseases." Brain Behav Immun. 2015 Jul 7. pii: S0889-1591(15)00236-6. doi: 10.1016/j.bbi.2015.07.002. https://pubmed.ncbi.nlm.nih.gov/26162709 ("We describe MCAD's pathogenesis, presentation (focusing on [central and/or peripheral neurologic and/or psychiatric symptoms] (NPS)), and therapy, especially vis-à-vis neuropsychotropes. Since MCAD patients often present NPS, neurologists and psychiatrists have the opportunity, in recognizing the diagnostic possibility of MCAD, to short-circuit the often decades-long delay in establishing the correct diagnosis required to identify optimal therapy.") |
Aschenbach et al. 2002 | Aschenbach JR, Ahrens F, Garz B, Gäbel G.: "Paracellular tightness and catabolism restrict histamine permeation in the proximal colon of pigs". Pflugers Arch. 2002 Oct;445(1):115-22. Epub 2002 Jul 16. https://www.ncbi.nlm.nih.gov/pubmed/12397395 |
B | Back to the previous position |
Bielenberg 2005 | Bielenberg, Jens: "Korrelate einer schadstoffinduzierten Veränderung des Histaminstoffwechsels? Die Allergie-Hypothese". Österreichische Apotheker-Zeitung ÖAZ Aktuell (Ausgabe 15/2005), Hauptartikel 15/2005. Anschrift des Autors: Apotheker Jens Bielenberg, Raphael-Apotheke, D-25364 Westerhorn, Bahnhofstr. 53 Der Artikel ist inzwischen online nicht mehr auffindbar. Ein sehr ähnlicher Text desselben Autors ist hier abrufbar: Bielenberg, Jens: "Die Allergie-Hypothese – Fakt oder Fiktion? Allergien - Korrelate einer schadstoffinduzierten Veränderung des Histaminstoffwechsels?". Ärztezeitschrift für Naturheilverfahren 46, 11 (2005).https://www.yumpu.com/de/document/view/6248824/die-allergie-hypothese-fakt-oder-fiktion-zentralverband-der- (Interessanter Artikel über mögliche Ursachen von Allergien, Störfaktoren im Histaminstoffwechsel, Abbaumechanismen von Histamin, Ascorbate (Vitamin C), Umweltschadstoffe, Schilddrüsenerkrankungen) |
Büttiker | Dr. med. U. Büttiker, Konsiliararzt Universitätsklinik Bern: "Histaminliberatoren", http://www.hautarzt-bubenberg.ch/sites/hautarzt-bubenberg.ch/files/pdf/Histaminliberatoren.pdf, abgerufen am 16.07.2011. |
C | Back to the previous position |
Cumming and Vincent 1992 | Cumming P, Vincent SR.: "Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by beta-carbolines." Biochem Pharmacol. 1992 Sep 1;44(5):989-92. https://pubmed.ncbi.nlm.nih.gov/1530666 ("Histamine-N-methyltransferase (HNMT), the major enzyme for the metabolism of histamine in rat brain, is potently inhibited by 9-amino-1,2,3,4-tetrahydroacridine (tacrine).") |
D | Back to the previous position |
Donatelli et al. 1994 | Donatelli, P., Marchi, G., Giuliani, L., Gustafsson, L.L., Pacifici, G.M.: "Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain.", Eur. J. Clin. Pharmacol. (1994). www.wikigenes.org/e/ref/e/7875186.html |
F | Back to the previous position |
Farag et al. 2008 | Farag NA, Mohamed SR, Soliman GA.: "Design, synthesis, and docking studies of novel benzopyrone derivatives as H(1)-antihistaminic agents." Bioorg Med Chem. 2008 Oct 1;16(19):9009-17. doi: 10.1016/j.bmc.2008.08.039. Epub 2008 Aug 26. https://pubmed.ncbi.nlm.nih.gov/18789706 ("histamine N-methyltranseferase (HNMT) active site in complex with its bound inhibitor (diphenhydramine)") |
Forth 2008 | Forth, Wolfgang; Hofmann, Franz; Förstermann, Ulrich: "Allgemeine und spezielle Pharmakologie und Toxikologie", 9. Auflage, Elsevier,Urban&Fischer Verlag, 2008. |
Fritzsche 2009 | Fritzsche, Doris: "GU Kompass Nahrungsmittel Intoleranzen, Laktose, Fruktose, Histamin", Gräfe und Unzer Verlag, 1. Auflage 2009. ISBN 978-3-8338-1368-9. |
G | Back to the previous position |
Giertz und Hahn 1966 | H. Giertz und F: Hahn: "Makromolekulare Histaminliberatoren", In: Mauricio Rocha e Silva (Hrsg.): Histamine and Anti-Histaminics Part 1. Handbuch der experimentellen Pharmakologie Band XVIII/1. Berlin, Springer-Verlag 1966, hier Seite 481–568 |
Gilfillan and Beaven 2011 | Gilfillan AM, Beaven MA.: "Regulation of mast cell responses in health and disease." Crit Rev Immunol. 2011;31(6):475-529. https://pubmed.ncbi.nlm.nih.gov/22321108 (Das Antibiotikum Novalgin ist ein Histaminliberator.) |
H | Back to the previous position |
Horton et al. 2005 | Horton JR, Sawada K, Nishibori M, Cheng X.: "Structural basis for inhibition of histamine N-methyltransferase by diverse drugs". J Mol Biol. 2005 Oct 21;353(2):334-44. https://pubmed.ncbi.nlm.nih.gov/16168438 (Medikamentenwirkstoffe als HNMT-Blocker: Folgende Stoffe, von denen bekannt ist, dass sie starke HNMT-Inhibitoren sind, wurden darauf hin untersucht, auf welche Weise sie den Histaminabbau blockieren: Diphenhydramine (ein H1-Antihistaminikum!), Amodiaquine, Metoprine, Tacrine. Alle blockieren die Histamin-Bindungsstelle des Enzyms, so dass kein Histamin mehr zum aktiven Zentrum der HNMT gelangen kann.) |
I | Back to the previous position |
Irion 2009 | Dr. Roland Irion: Internetseite "Biogene Amine. Auslöser von pseudoallergischen Reaktionen". http://www.alles-zur-allergologie.de/Allergologie/Artikel/3526/Allergen,Allergie/Biogene%20Amine/, abgerufen am 30.04.2013. |
J | Back to the previous position |
Jarisch 2004 | Jarisch, Reinhart: "Histamin-Intoleranz, Histamin und Seekrankheit", Thieme Verlag, 2004, ISBN 3-13-105382-8. |
Jarisch 2005 | Jarisch, Reinhart: "Histamin-Intoleranz: Ein oft übersehenes Problem". Arzt & Praxis VerlagsGmbH, Wien, Sonderdruck Oktober 2005, Heft Nr. 908, S. 380-382, 59. Jahrgang. http://www.reizmageninfo.de/ArztPraxis_2005_Jarisch.pdf, abgerufen am 08.11.2009 (inzwischen nicht mehr abrufbar). |
Jochem 2004 | Jochem J.: "Cardiac and regional haemodynamic effects of histamine N-methyltransferase inhibitor metoprine in haemorrhage-shocked rats." Inflamm Res. 2004 Jul;53(7):316-23. Epub 2004 Jun 25. https://pubmed.ncbi.nlm.nih.gov/15241567, Metoprin = HNMT-Hemmer |
K | Back to the previous position |
Komericki et al. 2010 | Peter Komericki, Georg Klein, Norbert Reider, Thomas Hawranek, Tanja Strimitzer, Roland Lang,Bettina Kranzelbinder, Werner Aberer: "Histamine intolerance: lack of reproducibility of single symptoms by oral provocation with histamine: A randomised, double-blind, placebo-controlled cross-over study", Wien Klin Wochenschr (2010). DOI 10.1007/s00508-010-1506-y. https://pubmed.ncbi.nlm.nih.gov/21165702, http://pubget.com/paper/21165702, abgerufen am 11.12.2011. Erfolgreicher Wirksamkeitsnachweis von Diaminoxidasepräparaten (DAOSIN). Zudem wurde gezeigt, dass das Auftreten einzelner Symptome nicht reproduzierbar ist. Es ist sinnlos, eine Korrelation zwischen der Histaminbelastung und einem bestimmten Symptom zu suchen. Man sollte in Studien immer die gesamte Palette der histaminvermittelten Symptomatik als Ganzes erfassen. |
L | Back to the previous position |
Livingstone 2013 | Dr. med. Elisabeth Livingstone, PD Dr. med. Uwe Hillen, PD Dr. med. Andreas Körber: "Unerwünschte Arzneimittelreaktionen" PowerPoint Präsentation Universitätsklinikum Essen. www.uk-essen.de/fileadmin/user_upload/hautklinik/fuer_studenten/arzneireaktionen_livingstone_23_05_2013.pdf (nicht mehr abrufbar) |
M | Back to the previous position |
Mathelier-Fusade 2006 | Mathelier-Fusade P.: "Drug-induced urticarias" Clin Rev Allergy Immunol. 2006 Feb;30(1):19-23. https://pubmed.ncbi.nlm.nih.gov/16461991 Gelesen in Gilfillan and Beaven 2011. (Das Antibiotikum Novalgin ist ein DAO-Inhibitor.) |
Medivere GmbH | ganzimmun.ch: "Ernährungsempfehlungen bei Histamin-Intoleranz", Medivere GmbH. http://www.histaminose.de/07_pdf/histamin.pdf, abgerufen am 06.12.2009 (inzwischen nicht mehr abrufbar). www.ganzimmun.ch/seiten/download_file.php?download_id=1855, abgerufen am 1.9.2014. |
N | Back to the previous position |
Nesterenko 2010 | Nesterenko, Sigi: "Histaminintoleranz - die unentdeckte Krankheit", Rainer Bloch Verlag, 2010, ISBN-10: 3981095189, ISBN-13: 978-3981095180. |
Novartis 2008 | Novartis: "FACHINFORMATION Program® 40, Suspension zur Injektion für Katzen", Juli 2008. http://www.ah.novartis.de/platform/content/element/1612/ProgramInj40-Katze.pdf, abgerufen am 12.2.2013. ("Nicht bei Hunden anwenden. Der Hilfsstoff Polyvinylpyrrolidon (Povidon) ist für Hunde eine starke Histamin freisetzende Substanz. Beim Hund können deshalb, im Gegensatz zuKatzen, schwere Reaktionen auftreten.") Anm. d. Red.: Hunde erkranken besonders häufig an Mastozytomen oder Mastzellsarkomen. Ein Indiz, dass Mastozytosepatienten auf Povidon vielleicht ähnlich empfindlich reagieren könnten wie Hunde? |
O | Back to the previous position |
O'Sullivan et al. 2006 | O'Sullivan J, O'Sullivan MI, Tipton KE, Davey G.: "Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine". J Neural Transm Suppl. 2006;(71):105-12. https://pubmed.ncbi.nlm.nih.gov/17447421 (Hydroxyzine (ein H1-Antihistaminikum!) blockiert die DAO.) |
P | Back to the previous position |
Pedersen et al. 2015 | Pedersen SH, Ramachandran R, Amrutkar DV, Petersen S, Olesen J, Jansen-Olesen: "Mechanisms of glyceryl trinitrate provoked mast cell degranulation." Cephalalgia. 2015 Feb 27. pii: 0333102415574846. https://pubmed.ncbi.nlm.nih.gov/25724914 (Intravenös verabreichtes Glyceroltrinitrat (Nitroglyzerin) führt einige Stunden nach der Injektion zu starker Mastzelldegranulation. Mechanismus noch unbekannt.) |
S | Back to the previous position |
Sattler et al. 1987 | Sattler J, Hesterberg R, Schmidt U, Crombach M, Lorenz W.: "Inhibition of intestinal diamine oxidase by detergents: a problem for drug formulations with water insoluble agents applied by the intravenous route?" Agents Actions. 1987 Apr;20(3-4):270-3. https://pubmed.ncbi.nlm.nih.gov/3111194 (Intravenös verabreichte Medikamente enthalten oft Detergentien/Tenside als Hilfsstoffe. Mehrere dieser Detergentien erwiesen sich als DAO-Hemmer und könnten für Unverträglichkeitsreaktionen auf Medikamente verantwortlich sein.) |
Sattler et al. 1985 | Sattler J, Hesterberg R, Lorenz W, Schmidt U, Crombach M, Stahlknecht CD.: "Inhibition of human and canine diamine oxidase by drugs used in an intensive care unit: relevance for clinical side effects?" Agents Actions. 1985 Apr;16(3-4):91-4. https://pubmed.ncbi.nlm.nih.gov/3925736 (Liste unverträglicher Medikamente (DAO-Hemmer)) |
Steneberg 2007 | Steneberg, Andreas: "Biogene Amine – Ernährung bei Histamin-Intoleranz", Umwelt & Gesundheit 2/2007. http://www.iug-umwelt-gesundheit.de/pdf/072_47_56_SP_HIT_neu.pdf, abgerufen am 06.11.2009. |
T | Back to the previous position |
Taraschenko et al. 2005 | Taraschenko OD, Barnes WG, Herrick-Davis K, Yokoyama Y, Boyd DL, Hough LB.: "Actions of tacrine and galanthamine on histamine-N-methyltransferase." Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):161-5. https://pubmed.ncbi.nlm.nih.gov/15834447 ("Tacrine (0.01-10 microM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT [...]. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for Alzheimer's disease.") |
U | Back to the previous position |
Uni Bochum | Klinik für Dermatologie, Venerologie und Allergologie, Ruhr-Universität Bochum – St. Josef-Hospital: "Patienteninformation Mastozytose", undatiert. http://www.derma.de/bochum/tl_files/dermatologie/dermatologie-pdf/Informationsblaetter/Merkblaetter_Mastozytose.pdf, abgerufen am 23.12.2014. |
Y | Back to the previous positione |
Yokoyama 2007 | Yokoyama A, Mori S, Takahashi HK, Kanke T, Wake H, Nishibori M: "Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice", Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. Epub 2006 Nov 22. https://pubmed.ncbi.nlm.nih.gov/17222819, abgerufen am 13.06.2010. |